Study S000643

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Assess the Efficacy and Safety of IBI362 in Chinese Subjects With Moderate-to-Severe Obstructive Sleep Apnea and BMI≥28 kg/m2 (GLORY-OSA)

ClinicalTrials.gov record

Registration

Registration: NCT06931028
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: RECRUITING
Enrollment: 260
Start: 2025-06-12
Primary completion: 2027-05-07
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Sleep Apnea; Obstructive; Obesity
Interventions: OTHER:placebo; DRUG:IBI362
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from Baseline in Apnea-Hypopnea Index (AHI) [Week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.